They found that ICAM3 was associated with a lower risk of T2D through a baseline follow-up of up to 16 years (median), as well as in quantitative analysis of multiple molecules, including ICAM3, in 2,224 participants from the EPIC-Heidelberg cohort. Here, ICAM3 is linked to type 2 diabetes mellitus.